Bristol-Myers Squibb Co. is upping its commitment to Five Prime Therapeutics Inc. and the antibody developer’s colony stimulating factor 1 receptor (CSF1R) antibody program with a new global licensing deal announced Oct. 15.
The deal replaces an existing clinical collaboration between the two companies signed in November 2014 to study Five Prime’s lead...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

